参考文献/References:
[1]Schmitz J, Owyang A, Oldham E, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines[J] .Immunity, 2005, 23 (5): 479-490.
[2] Demyanets S, Kaun C, Pentz R, et al. Components of the interleukin-33/ST2 system are differentially expressed and regulated in human cardiac cells and in cells of the cardiac vasculature[J].J Mol Cell Cardiol, 2013, 60: 16-26.
[3] Altara R, Ghali R, Mallat Z, et al. Conflicting vascular and metabolic impact of the IL-33/sST2 axis[J] . Cardiovasc Res, 2018, 114 (12): 1578-1594.
[4] 马波. 血清白介素-33水平与C-反应蛋白及冠状动脉病变程度关系的研究[D].苏州大学,2017.
[5] McLaren JE, Michael DR, Salter RC, et al. IL-33 reduces macrophage foam cell
formation[J]. J Immuno1,2010,185(2):1222-1229.
[6] Palmer G, Lipsky BP, Smithgall MD, et al. The IL-1 receptor accessory protein ( AcP) is required for IL-33 signaling and soluble AcP enhances the ability of soluble ST2 to inhibitIL-33[J]. Cytokine, 2008, 42 (3):358 -364.
[7]Demyanets S, Kaun C, Pentz R, et a l. Components of the interleukin-33/ST2 system are differentially expressed and regulated in human cardiac cells and in cells of the cardiac vasculature[J]. J Mol Cell Cardiol,2013,60:16-26.
[8]Liew FY, Girard JP, Turnquist HR. Interleukin-33 in health and disease[J]. Nat Rev Immunol,2016,16:676-689.
[9] Sanada S, Hakuno D, Higgins LJ, et al. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system[J].J Clin Invest,2007, 117:1538- 1549.
[10]王建旗,史旭波,马长生,等.炎症预测和预防动脉粥样硬化性心血管事件的研究进展[J].心血管病学进展,2018,39(5):687-690.
[11]刘丹.白介素-33对高糖诱导心肌细胞凋亡的保护作用及机制研究[D].武汉大学,2016.
[12]Miller AM, Xu D, Asquith DL, et al. IL-33 reduces the development of atherosclerosis[J]. J Exp Med ,2008,205(2):339-346.
[13] Mueller T, Jaffe AS. Soluble ST2—analytical considerations[J]. Am
J Cardiol,2015,115(7):8B-21B.
[14] Ye F, Wang JA, Daugherty A, et al. Macrophage-mediated mechanisms in atherosclerosis:still tangled[J]. Curr Opin Lipidol, 2017, 28 (3):286-287.
[15]Engelbertsen D, Lichtman AH. Innate lymphoid cells in atherosclerosis[J]. Eur J Pharmacol ,2017,816:32-36.
[16]Cardilo-Reis L, Gruber S, Schreier SM, et al. Interleukin-13 protects from atherosclerosis and modulates plaque composition by skewing the macrophage phenotype[J]. EMBO Mol Med ,2012,4(10):1072-1086.
[17]Min SY, Kady J, Nam M, et al. Human ’ brite/beige’ adipocytes develop from capillary networks, and their implantation improves metabolic homeostasis in mice[J]. Nat Med 2016;22 (3):312-318.
[18]Zhang C, Li L, Feng K, et al. ’Repair’ treg cells in tissue injury[J]. Cell Physiol Biochem ,2017,43(6):2155-2169.
[19] Wang YP, Wang JH, Wang XL,et al. Roles of ST2, IL-33 and BNP in predicting major adverse cardiovascular events in acute myocardial infarction after percutaneous coronary intervention[J].J Cell Mol Med, 2017, 21 (11): 2677-2684.
[20] Liu X, Hu Y, Huang W,et al. Soluble ST2 for prediction of clinical outcomes in patients with ST-segment elevation myocardial infarction receiving primary PCI[J] .Int Heart J, 2019, 60 (1): 19-26.
[21] Lupón J, Cediel G, Moliner P,et al. A bio-clinical approach for prediction of sudden cardiac death in outpatients with heart failure: The ST2-SCD score[J]. Int J Cardiol, 2019,293:148-152.
[22] Grakova EV,Kopeva KV, Teplyakov AT,et al. Prognostic role of ST2 in patients with chronic heart failure of ischemic etiology and carbohydrate metabolism disorders[J]. Ter Arkh, 2019, 91(1):32-37.
[23] 燕亚茹,刘美霞.血清可溶性ST2水平与心力衰竭的相关性研究[J].心血管病学进展,2018,39(2):214-217.
[24] Lepoj?rvi ES, Piira OP, Kiviniemi AM,et al. Usefulness of highly sensitive troponin as a predictor of short-term outcome in patients with diabetes mellitus and stable coronary artery disease (from the ARTEMIS Study)[J].Am J Cardiol, 2016, 117(4):515-521.
[25]Pfetsch V, Sanin V, Jaensch A, et al. Increased plasma concentrations of soluble ST2 independently predict mortality but not cardiovascular events in stable coronary heart disease patients:13-year follow-up of the KAROLA Study[J]. Cardiovasc Drugs Ther ,2017,31(2):167-177.
[26]O’Donoghue ML,Morrow DA,Cannon CP,et al. Multimarker risk stratification in patients with acute myocardial infarction[J].J Am Heart Assoc,2016,5(5). pii: e002586.
[27]Barbarash O, Gruzdeva O, Uchasova E,et al. Prognostic value of soluble ST2 during hospitalization for ST-segment elevation myocardial infarction[J].Ann Lab Med, 2016, 36(4): 313-319.
[28]Marino R, Magrini L, Orsini F,et al. Comparison between soluble ST2 and high-sensitivity troponin I in predicting short-term mortality for patients presenting to the emergency department with chest pain[J].Ann Lab Med, 2017, 37(2): 137-146.
[29] Jenkins WS, Roger VL, Jaffe AS, et al. Prognostic value of soluble ST2 after myocardial infarction:a community perspective[J].Am J Med, 2017, 130(9): 1112.e9-1112.e15.
[30] Demyanets S, Tentzeris I, Jarai R,et al. An increase of interleukin-33 serum levels after coronary stent implantation is associated with coronary in-stent restenosis[J].Cytokine, 2014, 67(2): 65-70.
[31] Tu X, Nie S, Liao Y, et al. The IL-33 —ST2L pathway is associated with coro nary artery disease in a Chinese Han population[J]. Am J Hum Genet, 2013, 93 (4):652-660 .
[32]Angeles-Martínez J, Posadas- Sánchez R, Llorente L,et al. The rs7044343 polymorphism of the interleukin 33 gene is associated with decreased risk of developing premature coronary artery disease and central obesity, and could be involved in regulating the production of IL-33[J].PLoS ONE, 2017, 12 (1): e0168828.
[33] Nie SF, Zha LF, Fan Q,et al. Genetic regulation of the thymic stromal lymphopoietin (TSLP)/TSLP receptor (TSLPR) gene expression and influence of epistatic interactions between IL-33 and the TSLP/TSLPR axis on risk of coronary artery disease[J].Front Immunol, 2018, 9: 1775.